Given the PD-1/PD-L1 ICIs could remove some of the immunosuppressant effect on the central and peripheral tolerance to cancer vaccines, they have been increasingly used in combination with neoantigen-based cancer vaccines to activate the specific T-cells for recognizing the tumor cells and kill them. Here, PDCD1 is linked to neoplasm.